Physician profile
Faiz M Uddin
NPI 1114900016
$3,520.70
in general payments reported to CMS, 2019-2025
28 companies · $953 in 2025
The $953 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2020: $511 · 2021: $579 · 2022: $405 · 2023: $450 · 2024: $462 · 2025: $953.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,865.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,864.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $811.22 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Glaxosmithkline, LLC. | $400.05 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Pfizer INC. | $329.47 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $316.93 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $216.99 | 2020-2024 | Ozempic, Rybelsus |
| Viatris Specialty LLC | $194.33 | 2025 | Yupelri |
| Lilly USA, LLC | $165.87 | 2019-2023 | Jardiance, Mounjaro |
| Mylan Specialty L.P. | $159.35 | 2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.77 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $118.59 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $89.96 | 2022 | |
| Allergan, INC. | $84.94 | 2020 | |
| Xeris Pharmaceuticals, INC. | $64.56 | 2022 | |
| Seqirus USA INC | $53.25 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.65 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $45.95 | 2022-2023 | Livalo, Seglentis |
| Bayer Healthcare Pharmaceuticals INC. | $43.91 | 2024 | |
| Sunovion Pharmaceuticals INC. | $37.00 | 2021 | |
| Astellas Pharma US INC | $33.37 | 2021 | |
| Abbott Laboratories | $28.82 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.59 | 2020 | |
| Axsome Therapeutics, INC. | $24.00 | 2025 | Auvelity |
| Esperion Therapeutics, INC. | $22.33 | 2021 | |
| Smith+Nephew, INC. | $17.51 | 2023 | Collagenase Santyl |
| Janssen Pharmaceuticals, INC | $15.57 | 2024 | Xarelto |
| Amryt Pharma Holdings LTD | $14.99 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.17 | 2025 | Caplyta |
| Amarin Pharma, INC. | $11.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faiz Uddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.